drugset / Trial / NCT05819684
A Study of SHR-4602 in Subjects With Advanced Malignant Solid Tumors
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is an open-label, three-part study to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of SHR-4602 and preliminary anti-tumor efficacy in HER2 expressing or mutated advanced malignant solid tumor subjects.
Timeline
- Start
- 2023-04-18
- Primary completion
- 2025-05-30
- Completion
- 2026-05-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SHR-4602 | Monoclonal antibody | — | Intravenous |